Estrella Immunopharma

ESLA · NASDAQ

$0.40+$0.0201 (+5.29%)TodayMarket closed · Oct 20, 7:50 PM ET

Prev close $0.3799

ESLA analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 3 analysts

Average $12.24 (+2960.0% upside)

Low: $12.12
Now: $0.40
High: $12.60

Upgrades and downgrades

The latest rating actions, newest first

ESLA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
D. Boral Capital	Feb 9, 2026	Maintains	Buy	$8.00	29%
D. Boral Capital	Jan 28, 2026	Maintains	Buy	$16.00 → $8.00	29%
D. Boral Capital	Nov 3, 2025	Maintains	Buy	$16.00	29%

The case for and against

Updated Jul 21, 2026

Bull case

Estrella Immunopharma is poised to disrupt the field of immunotherapy with its innovative CD19 and CD22-targeted ARTEMIS T-cell therapies, providing a promising treatment option for patients with blood cancers and solid tumors. With the ongoing success of its STARLIGHT-1 study and strong commentary from management, the company is making strides in advancing its clinical program and has extended its operational runway with its recent capital raise. Despite its recent decline, the potential for future partnerships and market opportunities in the field of CAR-T therapy make Estrella Immunopharma a strong long-term investment with a conservative target price of $8.00.

Bear case

Estrella Immunopharma is a clinical-stage biopharmaceutical company with a negative outlook due to concerns about the success of their ARTEMIS T-cell therapy platform. The company's valuation is based on only a 30% probability of success and a 30% discount rate, indicating limited confidence in their potential. While they have entered Phase II with their EB103 treatment, there are concerns about its ability to address limitations of existing CAR-T therapies and the company's cash burn and potential future raises raise further concerns about their long-term prospects.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.